Brief: Inovio Announces Orphan Drug Designation For INO-3107 From European Commission
23/05/2023 22:46
May 23 (Reuters) - Inovio Pharmaceuticals Inc INO.O :
* INOVIO ANNOUNCES ORPHAN DRUG DESIGNATION FOR INO-3107 FOR
THE
TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS FROM THE
EUROPEAN COMMISSION
Source text for Eikon: ID:nPn2M2qVta
Further company coverage: INO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inovio Pharmaceuticals
See all newsBrief: Inovio Announces Favorable Judgment In Litigation With Vgxi, Inc. And Geneone Life Science
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Inovio Q2 net loss narrows on warrant gain, lower costs
Brief: Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million